An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global…

AbbVie

Inventiva completes €48M IPO to fund phase 2b NASH trial

AbbVie hoping for early data readout for anti-tau Alzheimer's drug

AbbVie unveils clutch of I-O, genomics research pacts

AbbVie, Galapagos’ Kalydeco challenger clears phase 2

AbbVie’s phase 2 PARP study misses survival endpoints; hopes rest on bigger phase 3

AbbVie pens oncology research pacts with academic teams

AbbVie drops Halozyme formulation of blockbuster Humira after disappointing trial

Editor's Corner: Top 10 FierceBiotech articles of 2016